Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2 Part Phase 2 Trial to Evaluate ZD1839 (Iressa™) & Radiotherapy in Patients w/Locally Advanced Inoperable Squamous Cell Carcinoma of the Head & Neck

NCT00233636 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00233636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00233636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2 Part Phase 2 Trial to Evaluate ZD1839 (Iressa™) & Radiotherapy in Patients w/Locally Advanced Inoperable Squamous Cell Carcinoma of the Head & Neck
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Withdrawn
Start date
July 31, 2003
Completion date
Not reported
Enrollment
28
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell, head and neck cancer